The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success. This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025, according to GlobalData’s Pharmaceutical Intelligence […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!